Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SB-480848 in Major Adverse Cardiovascular Events - Integrated Phase III Summary of Efficacy and Safety

NCT01636271 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01636271
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01636271 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SB-480848 in Major Adverse Cardiovascular Events - Integrated Phase III Summary of Efficacy and Safety
Lead sponsor
GlaxoSmithKline
Phase
Observational
Overall status
Completed
Start date
October 31, 2011
Completion date
April 30, 2014
Enrollment
28,855 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

coronary heart disease